Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649494 | 0.93 | DRD4 (0.87) | DRD4SIGMAR1L3MBTL1MAPTKDM4E | |
| SCHEMBL6030916 | 0.91 | MAPT (0.83) | DRD4SIGMAR1L3MBTL1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL6030550 | 0.89 | MAPT (0.81) | DRD4SIGMAR1L3MBTL1MAPTKDM4E | |
| SCHEMBL6031812 | 0.89 | DRD4 (1.00) | DRD4SIGMAR1KDM4EALDH1A1HTR7 | |
| SCHEMBL15937826 | 0.88 | DRD4 (0.78) | DRD4SIGMAR1L3MBTL1MAPTKDM4E | |
| SCHEMBL6794331 | 0.86 | DRD4 (0.79) | DRD4SIGMAR1L3MBTL1ALDH1A1GAA | |
| SCHEMBL654308 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1L3MBTL1MAPTKDM4E | |
| SCHEMBL2876563 | 0.84 | DRD4 (1.00) | DRD4SIGMAR1GAAHTR7DRD2 | |
| SCHEMBL5548733 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1L3MBTL1GAAHTR7 | |
| SCHEMBL7512967 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1L3MBTL1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066163-A3 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
| EP-1441728-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| WO-2003037338-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1233955-A4 | PROCESS FOR PREPARING PIPERAZINE-SUBSTITUTED ALIPHATIC CARBOXYLATES | SALSBURY CHEMICALS INC (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1233955-A1 | PROCESS FOR PREPARING PIPERAZINE-SUBSTITUTED ALIPHATIC CARBOXYLATES | Salsbury Chemicals, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001032641-A1 | PROCESS FOR PREPARING PIPERAZINE-SUBSTITUTED ALIPHATIC CARBOXYLATES | SALSBURY CHEMICALS, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | DRD4 455/4885SIGMAR1 2866/4885L3MBTL1 4374/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | DRD4 4640/4885SIGMAR1 3962/4885L3MBTL1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.